Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects

Healthy Clinical Trial

Official title:

A Randomised, Open-Label, Food Effect and Formulation Bioavailability Study of Two Vamifeport Oral Formulations in Healthy Male and Female Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05077436
• Other study ID #: VIT-2763-CP-103
• Secondary ID: 2021-003187-27
• Status: Completed
• Phase: Phase 1
• Start date: October 14, 2021
• Est. completion date: January 5, 2022

Study information

• Verified date: January 2022
• Source: Vifor Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Two different vamifeport oral formulations will be administered in fed and fasted state to assess the vamifeport food-drug interaction and to assess the relative bioavailability (the proportion of drug entering the circulation) of 2 different vamifeport oral formulations in healthy adult participants.

Participants will be randomly allocated to one of four treatment sequences, with four dosing periods each, where different combinations of both formulations will be administered following fasted and fed state.

The total study duration for each participant is up to 7 weeks and 4 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: January 5, 2022
• Est. primary completion date: December 29, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Healthy participant. Healthy status defined by the Investigator.

• A body weight between 50 and 100 kg inclusive at screening.

• Non-smokers, or former smokers.

• Both female and male participants must agree to comply with the birth control requirements for the study.

• Ability to understand the requirements of the study and abide by the study restrictions, and agreement to return for the required assessments.

Exclusion Criteria:

• History of clinically significant gastrointestinal, cardiovascular, musculoskeletal, endocrine, neurological, hematological, psychiatric, renal, hepatic, bronchopulmonary, allergic or lipid metabolism disorders, cancer, or drug hypersensitivity.

• Any clinically relevant abnormal 12-lead ECG finding during screening or prior to randomization.

• A clinically relevant history of drug or alcohol misuse or abuse within 2 years prior to screening.

• Positive qualitative or semi-quantitative test for drugs of abuse positive cotinine screen (used to detect recent nicotine use), or alcohol breath test at screening (Visit 1) or Study Day -1 (Visit 2). Use of any of these agents will be not permitted during study participation.

• Strenuous physical exercise within the 1 week prior to Visit 2/Study Day -1 admission, and until completion of safety follow-up assessments are completed.

• Female participants who are pregnant or breastfeeding.

• Any concomitant medication (including herbal remedies and vitamins) taken within 2 weeks prior to Visit 2.

• Concomitant use of hormonal contraceptives (contraception associated with inhibition of ovulation), which are metabolized through cytochrome P450 (CYP) 3A4.

• Any other investigational drug.

• Blood draw or blood donation of =20 to <200 ml within 2 weeks, =200 to <400 ml within 4 weeks, or =400 ml within 12 weeks (male) or within 16 weeks (female) prior to Visit 2.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Vamifeport Formulation 1
Vamifeport Formulation 1 is available as 60 mg oral capsules
• Vamifeport Formulation 2
Vamifeport Formulation 2 is available as 60 mg oral capsules

Locations

Country	Name	City	State
United Kingdom	Labcorp Clinical Research Unit Ltd.	Leeds

Sponsors (1)

Lead Sponsor	Collaborator
Vifor (International) Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration versus time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC0-last) of vamifeport		Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Primary	Area under the plasma concentration versus time curve from time 0 extrapolated to infinite time (AUC0-infinity) of vamifeport		Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Primary	Maximum observed concentration (Cmax) of vamifeport		Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Secondary	Time of maximum vamifeport plasma concentration (Tmax)		Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Secondary	Apparent terminal disposition phase half-life (tl/2)		Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Secondary	Apparent terminal disposition phase rate constant		Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Secondary	Apparent total clearance		Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose
Secondary	Apparent volume of distribution during the terminal disposition phase		Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose